Navigation Links
Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
Date:9/25/2007

HORSHAM, Pa., Sept. 25 /PRNewswire/ -- Findings from an international, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial evaluating ustekinumab (CNTO 1275) in the treatment of moderate to severe plaque psoriasis will be presented for the first time at the 21st meeting of the World Congress of Dermatology, which takes place from Sept. 30 to Oct. 5, 2007 in Buenos Aires, Argentina.

The presentation, entitled CNTO 1275 (anti-IL-12/23p40) Treatment of Psoriasis: Phase 3 Trial Results will take place on Wednesday, Oct. 3, 2007 from 11 a.m. to 1 p.m. local time (GMT +3:00; 10:00 a.m. to 12:00 p.m. EDT), Room A, La Rural Convention Center, Buenos Aires, Argentina.

These first reported findings will be the subject of a live press briefing and webcast, which will be broadcast from the World Congress of Dermatology on Wednesday, Oct. 3 at 2 p.m. EDT. Media and analysts are invited to register at http://www.CNTO1275WCD.com and listen live on Oct. 3 as investigators from the trial will review and discuss the data.

About Ustekinumab

Ustekinumab is a new, fully-human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis and is being investigated as an infrequently-administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in normalizing the immune system and that are also believed to play a role in immune-mediated inflammatory diseases.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies will market ustekinumab in all countries outside of the United States.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease that results from inflammation in the skin and overproduction of skin ce
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
5. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
6. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
7. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
9. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...wswire/ -- Reportlinker.com announces that a new m...e. ,, Pipettes & Pipettors - A Global Mark...m/p0164373/Pipettes--Pipettors---A-Global-Market-P...um=pr&utm_campaign=prnewswire ,, Pipettes...any research laboratory. Large-scale applications ...
(Date:11/20/2009)...Nov. 20 Boston Scientifi...it has received 510(k) clearance from the U.S. Foo...al to market its WallFlex® Fully Covered Esop...geal strictures (obstructions) caused by tumors in...geal cancer. ,, (Photo: http://www.newscom.c...
(Date:11/20/2009)...Newswire-FirstCall/ -- Smith & Nephew ( SNN, L...ce the signing of a technology development contrac...t may lead to the creation of a fracture fixation ...the limbs of soldiers who sustain battlefield inju...ch Projects Agency (DARPA), the central research a...
Breaking Medicine Technology:Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4Red Reflex Vision Exam Should Be Given to All Newborns Report Recommends 60862 1Red Reflex Vision Exam Should Be Given to All Newborns Report Recommends 60862 2Red Reflex Vision Exam Should Be Given to All Newborns Report Recommends 60862 3Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 60858 1Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 60858 2Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 60858 3Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th 14754 1Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th 14754 2Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th 14754 3
... 2007 - ACADIA Pharmaceuticals,Inc. (Nasdaq:ACAD) ... Phase II schizophrenia co-therapy trial with ACP-...erse agonist. The trial,evaluated ACP-103 co-thera...ommonly prescribed atypical antipsychotic drug, or.... The co-therapy,arms with ACP-103 demonstrated st...
...ire-FirstCall/ -- La Jolla,Pharmaceutical Company ... data for the Phase 3 trial of Riquent(R) (abetimu...rythematosus,("lupus" or "SLE"). The updated analy...s a definitive and significant dose response,betwe...compared,with placebo (p=0.0001). These interim da...
Other Medicine Technology:Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 2Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 3Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 4Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 5Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 6La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6
(Date:11/22/2009)... WASHINGTON, D.C. November 18, 2009 -- When peopl...parasites, which enter the body from the saliva of...pread to red blood cells. Inside the blood cells, ...dhesive proteins on the cell surface that change t.... , Experiments show that infected red blood cel...
(Date:11/22/2009)... HealthSmart, an innovative...nced that it has successfully completed a recapita...ompany’s other lenders. Silver Point Capita...nwich, Connecticut. This recapitalization allows ...ts business strategy. , , ...
(Date:11/21/2009)..., , WASHINGTON, Nov. 21 /PRNewswire-USNewswi... statement after the Senate voted to begin full de..., (Logo: http://www.newscom.com/cgi-bin/prnh/2008...ther historic step on the road to enacting health ...l hurdle, senators will now have an opportunity to...
(Date:11/21/2009)..., , LONDON, November 21, 2009 /PRNewswire-...est Test Test Test Test Test Test Test Test Test T...est Test Test Test Test Test Test,Test Test Test T... More test More test More test More test More ...test More test More test More test More test More,...
(Date:11/21/2009)... New Haven Dental Group mer... D.D.S of Branford, CT. , ... Group, comprised of partners Dr. David Gibson, Dr... Forrester has just merged their growing practice ...man., , ,When Dr. Pickman decided he wanted to ret...
Breaking Medicine News(10 mins):Health News:Measuring and modeling blood flow in malaria 2Health News:HealthSmart Completes Recapitalization to Support Continued Growth, Daniel D. Crowley Named Chairman 2Health News:Democratic National Committee Chairman Tim Kaine's Statement on the Senate's Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 2Health News:New Haven Dental Group Expands Their Vision 2
...tish Kumar is all for a giving a boost to herbal p...tivate potato, tomato and green vegetables// at th...ace as a resource centre for herbal farming. .... Even today Nitish's elder brother practises ayur...
...ermint and cinnamon odors can increase alertness a...ill Esgro an undergraduate student, has conducted ...his Professor, Dr. Bryan Raudenbush, Wheeling Jesu...driving. Cinnamon proved to better than it’s count...
...nization (WHO), there is an outbreak of apparent b...home-preserved// bamboo shoots. It has left more ...ailand. WHO further stated that according to the T...ized an almost 40 of them in need of respirators, ...
...ted among 8,000 men aged 16 to 59, it was found th...e almost 40 %// more likely to be impotent than no...oblems for a month or more in the previous year. T...ch as they think that it would discourage more peo...
...) after complete examination of the data put China...llion people suffer// from diabetics in china. Goj...c Diseases and Health Promotion said that WHO's ye...th objected to the figure. They said that the ...
...ion. In is one of the important secondary infectio...ium tuberculosis//. Lately the number of cases of ...d are on the rise. Statistics show that it has top...ains of the bacteria that cause TB. The various te...
Other Medicine News:Health News:Bamboo Shoots Causes Botulism Outbreak 2Health News:Smoking Is a Vital Cause among Impotent Men 2Health News:China Crowned the Diabetic Capital of the World 2
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
Medicine Products: